BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

@article{Iqbal2011BCL2PS,
  title={BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab},
  author={J. Iqbal and Paul N. Meyer and L. Smith and N. Johnson and J. Vose and T. Greiner and J. Connors and L. Staudt and L. Rimsza and E. Jaffe and A. Rosenwald and G. Ott and J. Delabie and E. Campo and R. Braziel and J. R. Cook and R. Tubbs and R. Gascoyne and J. Armitage and D. Weisenburger and W. Chan},
  journal={Clinical Cancer Research},
  year={2011},
  volume={17},
  pages={7785 - 7795}
}
Purpose: We have previously shown the prognostic significance of BCL2 expression in the activated B-cell–like diffuse large B-cell lymphoma (ABC-DLBCL) patients treated with cyclophosphamide-Adriamycin-vincristine-prednisone (CHOP) or CHOP-like therapy. However, after the inclusion of rituximab (R) in the CHOP regimen, several conflicting observations about the prognostic value of BCL2 expression have been reported. Experimental Design: We evaluated the R-CHOP cohort of 221 DLBCL cases with… Expand
154 Citations
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
  • N. Johnson, G. Slack, +28 authors R. Gascoyne
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
  • 693
BCL2/Ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma.
  • 13
BCL2 and subtype as prognostic and predictive markers of diffuse large B-cell lymphoma
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 74 REFERENCES
CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma
  • 72
Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP
  • 20
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
  • J. Iqbal, V. Neppalli, +19 authors W. Chan
  • Biology, Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
  • 198
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.
  • 97
Prognostic impact of immunohistochemical biomarkers in diffuse large B‐cell lymphoma in the rituximab era
  • 92
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
  • K. Fu, D. Weisenburger, +10 authors J. Vose
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
  • 292
...
1
2
3
4
5
...